Successful Polymyxin B Hemoperfusion Treatment Associated With Serial Reduction of Serum Anti-CADM-140/MDA5 Antibody Levels in Rapidly Progressive Interstitial Lung Disease With Amyopathic Dermatomyositis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article discusses the medical case of a 52-year-old man with rapidly progressive interstitial lung disease (RP-ILD) with clinically amyopathic dermatomyositis (CADM). The case showed the usefulness of determining the anti-CADM-140/MDA45 antibody levels by enzyme-linked immunosorbent assay to monitor the disease activity in patients with RP-ILD. Plymyxin-B direct hemoperfusion (PMX-DHP) helped reduce the antibody concentration.